BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

BioInvent receives EMA support for BI-1808

2025-11-18 17:04:00

BioInvent has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) regarding orphan drug designation for BI-1808 in cutaneous T-cell lymphoma. According to CEO Martin Welschof, this step – together with the encouraging clinical data generated to date – reinforces the company’s commitment to advancing BI-1808 as a novel immunotherapy for CTCL patients.

Read the article at biostock.se:

BioInvent receives EMA support for BI-1808

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Vem äger bolaget?

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden